Document:

EX-10.1

 Exhibit 10.1 

Portions of the exhibit, marked by brackets, have been omitted because 

the omitted information (i) is not material and (ii) is treated as confidential by the Company. 

																	
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT	 	 	 	1. CONTRACT ID CODE	 	PAGE OF PAGES
		 		 		 		 	    	 	    1	 	13
	2. AMENDMENT/MODIFICATION NO.	 	3. EFFECTIVE DATE	 	4. REQUISITION/PURCHASE REQ. NO.	 	5. PROJECT NO. (if applicable)            
		 	 	 		
	P00004	 	See Block 16C	 	OS300135	 	 	 	 	 	 
	6. ISSUED BY	 	CODE 	 	ASPR-BARDA	 	7. ADMINISTERED BY (if other than Item 6)	 	CODE 	 	
	  
 ASPR-BARDA

200 Independence Ave., S.W.
 Room
640-G
 Washington DC 20201
  
	 		 		 		 		 		 	
	8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)	 	 (x)

 
	 	 9A. AMENDMENT OF SOLICITATION NO.

 

	  
 CONTRAFECT CORPORATION 1576315

Attn: ANTHONY DINGER
 CONTRAFECT
CORPORATION            28 WELL
 28 WELLS AVE FL 3

YONKERS NY 10701
  
	 		 		 	  
 9B. DATED (SEE ITEM 11)

 

	 	x	 	10A. MODIFICATION OF CONTRACT/ORDER NO.
	 		 		 	75A50121C00021
	 		 		 	10B. DATED (SEE ITEM 13)
	CODE	 	1576315	 	FACILITY CODE	 	 	 	 	 	03/10/2021

													
	 
	
11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

 

	  

☐   The above numbered solicitation is amended as set forth in Item 14. The hour and date
specified for receipt of Offers             ☐ is extended.        ☐ is not extended.

       Offers must acknowledge receipt of this amendment prior to the hour and
date specified in the solicitation or as amended , by one of the following methods: (a) By completing Items 8 and 15, and returning
                     copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted ; or
(c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE
SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted , such change may be made by letter or electronic communication, provided each letter or electronic communication makes
reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	12. ACCOUNTING AND APPROPRIATION DATA (if required)	 	                        Net Increase	 	$6,614,714.00
					 
	2022.1992022.25106	 		 		 		 	 
	 
	
13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

 

	CHECK ONE	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	
A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE
IN THE CONTRACT ORDER NO. IN ITEM 10A.
  
  

	 	 	
B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in
paying office, appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).
  

 

	  

X
  
	 	 C. THIS
SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

	 	FAR 52.217-9 Option to Extend the Term of the Contract and 43.103(a) - Modification by mutual agreement o
		 	  

D. OTHER (Specify type of modification and authority)

 
  

	E. IMPORTANT:	 	
Contractor         ☐ is not         ☒ is required to sign this
document and return                          copies to the issuing office.

 

	  
 14. DESCRIPTION OF
AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
  

Tax ID Number: 39-2072586

DUNS Number: [***]
 UEI: LXUZL23QTTZ9

 
 The purpose of this modification is to: (1) descope CLIN 0002, exercise and fund
the newly established CLIN 0002 Option Period 1; (2) delete CLINs 0003-0006; (3) Revise Section B.3.(4) Revise the Contracting Officer in Section’s F.2, G.1, and G.5 (5) Revise the Statement of Work. See Block 14 Continuation Sheet.

 
 The total BARDA exercised share contract value, increased by $6,614,714.00 from
$9,767,226.00 to $16,381,940.00.
 Continued ...
  

Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force
and effect.
  
	 	 

													
	 	 
	15A. NAME AND TITLE OF SIGNER (Type or print)	 	16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
		 
	 Roger J. Pomerantz, M.D., F.A.C.P.

President and CEO
	 	JONATHAN F. GONZALEZ
		 	 	 
	15B. CONTRACTOR/OFFEROR	 	15C. DATE SIGNED  	 	16B. UNITED STATES OF AMERICA	 	16C. DATE SIGNED        
		 	 	 
	
/s/ Roger J. Pomerantz            
                  
   (Signature of person
authorized to sign)
	 	        August 23, 2022	 	 /s/ Jonathan F.
Gonzalez                                        
            

                    (Signature of Contracting
Officer)
	 	 2022.08.24

	  
	 		 		 		 		 		 	 

  

			
	Previous edition unusable	  	
STANDARD FORM 30 (REV. 11/2016)

Prescribed by GSA FAR (48 CFR) 53.243            

	NSN 7540-01-152-8067	  	
OPTIONAL FORM 336 (4-86)

Sponsored by GSA

FAR (48 CFR) 53.110

  

									
	 	 	 
	CONTINUATION SHEET	  	REFERENCE NO. OF DOCUMENT BEING CONTINUED	  	PAGE OF PAGES
	 		 	
	 	  	75A50121C00021/P00004	  	    1    	  	13

	
	 
	NAME OF OFFEROR OR CONTRACTOR
	CONTRAFECT CORPORATION 1576315

																							
	 	 	 	 	 	 
	
  ITEM NO.  

(A)
		SUPPLIES/SERVICES
(B)		
  QUANTITY  

(C)
		
  UNIT  

(D)
		
  UNIT PRICE  

(E)
		
    AMOUNT    

(F)

	 	 	 	 	 	 
	2		 Total Contract value (including
ContraFect Cost share), decreased by $121,748,377 from $170,905,385 to $49,157,008.00, due to the descoping of CLIN 0002 and the deletion of CLINs 0003-0006.

Appr. Yr.: 2022 CAN: 1992022 Object Class: 25106 Period of Performance: 03/15/2021 to 06/30/2023

 
 Add Item 2 as follows:

 
 ASPR-22-01866 Exercise CLIN 0002 (Option 1) to ContraFect Corp under contract 75A50121C00021 Obligated Amount: $6,614,714.00
								6,614,714.00
			  
  

    
  

 
								

  

									
	 	 	 	 
	NSN 7540-01-152-8067	  		  		  	
OPTIONAL FORM 336 (4-86)

Sponsored by GSA
 FAR (48 CFR)
53.110

			
	 Contract No.
 75A50121C00021

Modification No. P00004
	  	 Continuation Sheet

Block 14

  

 Beginning with the effective date of this modification, the Government and the Contractor mutually agree as
follows: 
 PART I – THE SCHEDULE 
 SECTION B
– SUPPLIES OR SERVICES AND PRICES/COSTS 
 ARTICLE B.2. ESTIMATED COST 

a. The base period consists of the cost share CLIN 0001 with an estimated cost total of $40,824,135. 

b. The amount currently obligated $9,767,226 will cover base performance of the contract through August 31, 2022. 

 

																					
	 Base Period Cost Share CLIN
	 
	 Item
	  	Period of
Performance	 	  	Supplies/Services	 	 	BARDA Share	 	  	ContraFect
Share	 	  	Total
(BARDA
share Plus
ContraFect
Share)	 
	 0001 Base
	  	 	3/15/21-8/31/22	 	  	 

	Conduct a Phase 3
clinical trial,
supportive
manufacturing, futility
analysis (60%) will be
conducted and
reviewed by the
DSMB	 
 
 
 
 
 
 
 	 	$	9,767,226	 	  	$	31,056,909	 	  	$	40,824,135	 
		  				  				 	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Total
	  				  				 	$	9,767,226	 	  	$	31,056,909	 	  	$	40,824,135	 
		  				  				 	  
	  
	 	  	  
	  
	 	  	  
	  
	 

 B.3. OPTION PERIODS 

B.3.1 COST REIMBURSEMENT OPTIONS 
 a. The contract includes
optional, cost share CLIN 0002. The Government may exercise Option Periods in accordance with FAR 52.217-9 Option to Extend the Term of the Contract (March 2000), as set forth in Section I of the contract.

 b. Unless the government exercises its option pursuant to the option clause contained in ARTICLE I.2, the contract consists only of the Base Work segment
specified in the Statement of Work as defined in SECTIONS C and F, for the price set forth in ARTICLE B.2 of the contract. 
 c. The Government may modify
the contract unilaterally and require the contractor to provide supplies and services for Option Periods listed below, in accordance with FAR 52.217-9. 

			
	 Contract No.
 75A50121C00021

Modification No. P00004
	  	 Continuation Sheet

Block 14

  

 d. If the Government decides to exercise an option(s), the Government will provide the Contractor a
preliminary written notice of its intent as referenced in the clause. Specific information regarding the timeframe for this notice is set forth in the option clause ARTICLE I.2 of this contract. The estimated cost share of the contract will be
increased as set forth below: 
  

																					
	 Optional Cost Share CLINs
	 
	 Item
	  	Period of
Performance	 	  	Supplies/Services	 	  	BARDA Share	 	  	ContraFect
Share	 	  	Total
(BARDA
share Plus
ContraFect
Share)	 
	 0002 (Option)
	  	 	9/1/22-6/30/23	 	  	 

	Phase 3 Clinical Trial
CF-301-105 close out
and root cause
analysis of futility
outcome	 
 
 
 
 	  	$	6,614,714	 	  	$	1,718,159	 	  	$	8,332,873	 
		  				  				  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Total
	  				  				  	$	6,614,714	 	  	$	1,718,159	 	  	$	8,332,873	 
		  				  				  	  
	  
	 	  	  
	  
	 	  	  
	  
	 

  

													
	 Total Funded BARDA Share
	  	$	16,381,940	 
		  		  		  		  		  	  
	  
	 

 SECTION F – DELIVERABLES OR PERFORMANCE 

F.2. DELIVERABLES 
 All paper/hardcopy documents/reports
submitted under this contract shall be printed or copied, 
 double-sided, on at least 30 percent post-consumer fiber paper, whenever practicable, in
accordance with FAR 4.302(b). Hard copies of deliverables and reports furnished to the Government under the resultant Contract (including invoices) shall be addressed as follows: 

HHS/ASPR/BARDA/CMA: 
 ATTN: Jonathan Gonzalez (Contracting
Officer) 
 U.S. Department of Health & Human Services 

Office of the Assistant Secretary for Preparedness and Response 

Biomedical Research and Development Authority (BARDA) 
 Contract
Management and Acquisition (CMA) 
 O’Neill House Office Building 

Washington, DC 20515 
 Email: [***] 

SECTION G - CONTRACT ADMINISTRATION DATA 
 G.1.
CONTRACTING OFFICER 

			
	 Contract No.
 75A50121C00021

Modification No. P00004
	  	 Continuation Sheet

Block 14

  

 The following Contracting Officer (CO) will represent the Government for the purpose of this contract: 

Jonathan Gonzalez (Contracting Officer) 
 U.S. Department of
Health & Human Services 
 Office of the Assistant Secretary for Preparedness and Response (ASPR) 

Biomedical Advanced Research and Development Authority (BARDA) 

Contract Management and Acquisition (CMA) 
 O’Neill House
Office Building 
 Washington, DC 20515 
 301-956-6588 
 Email: [***] 

G.3. KEY PERSONNEL 
 Pursuant to the Key Personnel clause
incorporated in Section I of this contract, the following individuals are considered to be essential to the work being performed hereunder: 
  

			
	 Name
	  	 Title

	[***]	  	Interim Chief Medical Officer
	[***]	  	VP Program Management & Development Operations
	[***]	  	Biometrics Consultant
	[***]	  	Regulatory Affairs Consultant
	[***]	  	Medical Affairs Consultant

 The key personnel specified in this contract are considered to be essential to work performance. At least [***] days prior to
diverting any of the specified individuals to other programs or contracts (or as soon as possible, if an individual must be replaced, for example, as a result of leaving the employ of the Contractor), the Contractor shall notify the Contracting
Officer and shall submit comprehensive justification for the diversion or replacement request (including proposed substitutions for key personnel) and qualifications of the individual proposed as a substitute to permit evaluation by the Government
of the impact on performance under this contract. The Contractor shall not divert or otherwise replace any key personnel without the written consent of the Contracting Officer. The Government may modify the contract to add or delete key personnel at
the request of the contractor or Government. 
 G.4. CONTRACT FINANCIAL REPORT 

 

					
	 CO
	  	 COR
	  	 PSC

	 Jonathan Gonzalez
 (Contracting Officer)

HHS/ASPR/BARDA/CMA
 O’Neill House Office Bldg

Washington, DC 20515
 Email: [***]
	  	 Kensey Amaya, PhD COR
 HHS/ASPR/BARDA

O’Neill House Office Bldg
 Washington, DC 20515

202-690-5746

Email: [***]
	  	 [***]

& “e-Room”

			
	 Contract No.
 75A50121C00021

Modification No. P00004
	  	 Continuation Sheet

Block 14

  

 PART III - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS SECTION J - LIST OF ATTACHMENTS 

The following documents are attached and incorporated in this contract: 
  

	1.	 Statement of Work 

Statement of Work, dated 08/18/2022 

			
	 Contract No.
 75A50121C00021

Modification No. P00004
	  	 Continuation Sheet

Block 14EX-10.8

   

  Exhibit 10.8

  SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT 

  THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of August 31, 2022, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and SYROS PHARMACEUTICALS, INC., a Delaware corporation with offices located at 840 Memorial Drive, Cambridge, MA 02139 (“Borrower”).

  A.	Collateral Agent, Borrower and Lenders have entered into that certain Loan and Security Agreement dated as of February 12, 2020 (as amended, supplemented or otherwise modified from time to time, the “Loan Agreement”) pursuant to which Lenders have provided to Borrower certain loans in accordance with the terms and conditions thereof; 

  B.	Borrower has requested that Collateral Agent and the Required Lenders modify certain provisions of the Loan Agreement; and 

  C.	Collateral Agent and the Required Lenders have agreed to amend certain provisions of the Loan Agreement, subject to, and in accordance with, the terms and conditions set forth herein, and in reliance upon the representations and warranties set forth herein.

  Agreement

  	NOW, THEREFORE, in consideration of the promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower, the Required Lenders and Collateral Agent hereby agree as follows:

  1.Definitions.  Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Loan Agreement.

  2.Amendments to Loan Agreement.

  2.1 Section 6.10 (Financial Covenant).  Section 6.10 of the Loan Agreement is amended and restated as follows:

  “6.10	MSC Investment Condition.  Borrower shall maintain unrestricted cash balance in one or more Control Accounts subject to Control Agreements in favor of Collateral Agent in an aggregate amount of not less than an amount equal to the lesser of (i) One Hundred Ten percent (110.00%) of the aggregate principal amount of outstanding Obligations (provided, however, for the period from August 1, 2022 through September 23, 2022 only, such percent during such period shall be Ninety percent (90.00%) of the aggregate principal amount of outstanding Obligations) and (ii) the amount of Borrower’s and all of its Subsidiaries’ (including Syros Securities) aggregate consolidated cash and Cash Equivalent assets (the “MSC Investment Condition”).”

  2.2 Compliance Certificate (Exhibit C).  Exhibit C to the Loan Agreement is amended by replacing the summary of the MSC Investment Condition with the following:

  “Not less than the lesser of (i) One Hundred Ten percent (110.00%) of the aggregate principal amount of outstanding Term Loans (provided, however, for the period from August 1, 2022 through September 23, 2022 only, such percent during such period shall be Ninety percent (90.00%) of the aggregate principal amount of outstanding Term Loans) and (ii) the amount of Borrower’s and all of its Subsidiaries’ aggregate consolidated cash and Cash Equivalent assets”.

  	1

  

   

  3.Limitation of Amendment.

  3.1 The amendments set forth in Section 2 above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as amended hereby.

  3.2 This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents are hereby ratified and confirmed and shall remain in full force and effect.

  4.Representations and Warranties.  To induce Collateral Agent and the Required Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and the Required Lenders as follows: 

  4.1 Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct in all material respects as of such date) and (b) no Event of Default has occurred and is continuing; 

  4.2 Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment; 

  4.3 The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by or on behalf of the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;  

  4.4 The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not contravene (i) any material law or regulation binding on or affecting Borrower, (ii) any material contractual restriction with a Person binding on Borrower, (iii) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower;

  4.5 The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made; 

  4.6 This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights. 

  5.Loan Document.  Borrower, Lenders and Collateral Agent agree that this Amendment shall be a Loan Document.  Except as expressly set forth herein, the Loan Agreement and the other Loan Documents shall continue in full force and effect without alteration or amendment.  This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.

  6.Release by Borrower.

  6.1 FOR GOOD AND VALUABLE CONSIDERATION, Borrower hereby forever relieves, releases, and discharges Collateral Agent and each Lender and their respective present or former employees, officers, directors, agents, representatives, attorneys, and each of them, from any and all claims, debts, liabilities, demands, obligations, promises, acts, agreements, costs and expenses, actions and causes of action, of every type, kind, nature, description 

  	2

  

   

  or character whatsoever, whether known or unknown, suspected or unsuspected, absolute or contingent, arising out of or in any manner whatsoever connected with or related to facts, circumstances, issues, controversies or claims existing or arising from the beginning of time through and including the date of execution of this Amendment solely to the extent such claims arise out of or are in any manner whatsoever connected with or related to the Loan Documents, the Recitals hereto, any instruments, agreements or documents executed in connection with any of the foregoing or the origination, negotiation, administration, servicing and/or enforcement of any of the foregoing (collectively “Released Claims”).

  6.2 By entering into this release, Borrower recognizes that no facts or representations are ever absolutely certain and it may hereafter discover facts in addition to or different from those which it presently knows or believes to be true, but that it is the intention of Borrower hereby to fully, finally and forever settle and release all matters, disputes and differences, known or unknown, suspected or unsuspected in relation to the Released Claims; accordingly, if Borrower should subsequently discover that any fact that it relied upon in entering into this release was untrue, or that any understanding of the facts was incorrect, Borrower shall not be entitled to set aside this release by reason thereof, regardless of any claim of mistake of fact or law or any other circumstances whatsoever.  Borrower acknowledges that it is not relying upon and has not relied upon any representation or statement made by Collateral Agent or Lenders with respect to the facts underlying this release or with regard to any of such party’s rights or asserted rights.

  6.3 This release may be pleaded as a full and complete defense and/or as a cross-complaint or counterclaim against any action, suit, or other proceeding that may be instituted, prosecuted or attempted in breach of this release.  Borrower acknowledges that the release contained herein constitutes a material inducement to Collateral Agent and the Lenders to enter into this Amendment, and that Collateral Agent and the Lenders would not have done so but for Collateral Agent’s and the Lenders’ expectation that such release is valid and enforceable in all events.

  7.Effectiveness. This Amendment shall be deemed effective as of the date hereof upon the due execution of this Amendment by the parties thereto. 

  8.Counterparts.  This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument.  Delivery by electronic transmission (e.g. “.pdf”) of an executed counterpart of this Amendment shall be effective as a manually executed counterpart signature thereof.

  9.Governing Law.  This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of New York.

   

  [Balance of Page Intentionally Left Blank]

   

   

  	3

  

   

  IN WITNESS WHEREOF, the parties hereto have caused this Second Amendment to Loan and Security Agreement to be executed as of the date first set forth above.

  			
	BORROWER:
	 
	 

	 
	 
	 

	SYROS PHARMACEUTICALS, INC.
	 
	 

	 
	 
	 

	 
	 
	 

	By /s/ Jason Haas
	 
	 

	Name: Jason Haas
	 
	 

	Title: Chief Financial Officer
	 
	 

	 
	 
	 

	 
	 
	 

	COLLATERAL AGENT AND LENDER:
	 
	 

	 
	 
	 

	OXFORD FINANCE LLC

	 
	 
	 

	 
	 
	 

	By /s/ Colette H. Featherly
	 
	 

	Name: Colette H. Featherly
	 
	 

	Title: Senior Vice President
	 
	 

	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	 
	 

	 
	 
	 

   

   

   

   

   

   

   

   

   

   

   

  [Signature Page to Second Amendment to Loan and Security Agreement]

  	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]